Loading organizations...
ArrowBiome is a Singapore-based biotechnology company that develops precision microbiome therapeutics utilizing proprietary lysin proteins to selectively target and eliminate harmful bacteria. The enterprise focuses on creating targeted alternatives to traditional broad-spectrum antibacterials for the healthcare and personal care industries, addressing conditions such as acne, body odor, and antimicrobial resistance. Operating as a spin-out from the National University of Singapore, the firm has raised $1 million in seed funding to support its clinical validation and commercialization initiatives. The venture is backed by notable institutional investors and research organizations, securing financial support from entities including Cocoon Capital and the Singapore-MIT Alliance for Research and Technology. The company recently advanced its commercial pipeline by introducing ArcherZyme, a clinically validated lysin ingredient designed for cosmetic applications. ArrowBiome was founded in 2022 by researchers Chong Goh and Matthew Chang.
ArrowBiome has raised $1.0M across 1 funding round.
ArrowBiome has raised $1.0M in total across 1 funding round.
ArrowBiome has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 18, 2024 | $1M Seed | Cocoon Capital | — | Announced |
ArrowBiome has raised $1.0M in total across 1 funding round.
ArrowBiome's investors include Cocoon Capital.
